Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amezinium metilsulfate is a sympathomimetic small molecule drug primarily used for the treatment of hypotensive states, including essential and orthostatic hypotension. It acts by stimulating alpha and beta-1 adrenergic receptors, inhibiting monoamine oxidase (MAO), and blocking neuronal uptake of noradrenaline and tyramine. These combined actions increase blood pressure by enhancing sympathetic tone and reducing norepinephrine breakdown or reuptake. The drug is administered orally, with typical side effects including palpitations, headache, nausea/vomiting, hot flashes, and hypertension[2][5][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amezinium metilsulfate.